<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03660293</url>
  </required_header>
  <id_info>
    <org_study_id>31499/04/17</org_study_id>
    <nct_id>NCT03660293</nct_id>
  </id_info>
  <brief_title>Prediction and Prevention of Asymptomatic Cardiovascular Insult in Type 1 Diabetic Children: Comparative Effectiveness of Cardioprotective Drugs</brief_title>
  <official_title>Prediction and Prevention of Asymptomatic Cardiovascular Insult in Type 1 Diabetic Children: Comparative Effectiveness of Cardio-protective Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic cardiomyopathy (DCM) is a distinct clinical entity of diabetic heart muscle that
      describes diabetes associated changes in the structure and function of the myocardium in the
      absence of coronary artery disease, hypertension, and valvular disease. Oxidative stress
      plays a critical role in DCM development. DCM can be diagnosed using the novel methods of
      echocardiography (tissue Doppler imaging, Speckling tracking techniques and more recent real
      time 4D echocardiography). There is a possible cardioprotective effect of statins, Captopril
      and L-Carnitine in type 1 diabetic children and adolescents.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Actual">June 1, 2019</completion_date>
  <primary_completion_date type="Actual">June 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The cardiac changes induced by Simvastatin, captopril and L-Carnitine in type 1 diabetic children and adolescents.</measure>
    <time_frame>before and after 4 months of receiving cardio-protective agents</time_frame>
    <description>Corrected QT interval(QTc) and QT dispersion in ElectroCardioGram</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The cardiac changes induced by Simvastatin, captopril and L-Carnitine in type 1 diabetic children and adolescents.</measure>
    <time_frame>before and after 4 months of receiving cardio-protective agents</time_frame>
    <description>Left Ventricular End Systolic Volume (ml). Left Ventricular End Diastolic Volume (ml). Ejection Fraction (EF %) and left ventricular strain using echocardiography.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The role of Troponin I levels as a cardiac marker for detection of asymptomatic cardiovascular insult in diabetic children.</measure>
    <time_frame>first day</time_frame>
    <description>Serum Cardiac troponin I by Enzyme Linked ImmunoSorbant Assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The role of recent echocardiographic parameters for early detection of silent myocardial dysfunction</measure>
    <time_frame>first day</time_frame>
    <description>Echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of risk factors for developing diabetic cardiac insult.</measure>
    <time_frame>first day</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>diabetic- no cardioprotectives</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>25 child with type 1 diabetes mellitus will not receive any cardio protective drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>diabetic-Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 child with type 1 diabetes mellitus will receive Statin (2 mg/kg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>diabetic-Captopril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 child with type 1 diabetes mellitus will receive Captopril (0.2 mg/kg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>diabetic-L-Carnitine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 child with type 1 diabetes mellitus will receive L-carnitine (50 mg/kg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>50 healthy children, of matched age and sex, with no symptoms of cardiac diseases</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>cardio-protective agents</description>
    <arm_group_label>diabetic-Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Captopril</intervention_name>
    <description>cardio-protective agents</description>
    <arm_group_label>diabetic-Captopril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-carnitine</intervention_name>
    <description>cardio-protective agents</description>
    <arm_group_label>diabetic-L-Carnitine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children and adolescent suffering from type 1 Diabetes Mellitus, for at least 3 years
             from the onset of the disease.

        Exclusion Criteria:

          -  Children with Congenital Heart Diseases.

          -  Children with acquired cardiac diseases.

          -  Children with other systemic diseases.

          -  Symptomatic diabetic cardiomyopathy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculty of Medicine- Tanta University</name>
      <address>
        <city>Tanta</city>
        <state>Gharbia</state>
        <zip>0000</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2018</study_first_posted>
  <last_update_submitted>June 14, 2019</last_update_submitted>
  <last_update_submitted_qc>June 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Rasha Mohamed Gamal</investigator_full_name>
    <investigator_title>Ass. Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Captopril</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

